Domestic brokerage JM Financial, which initiated coverage on the stock with a Buy rating, values the stock at 4x Sep’24e P/BV to arrive at a target price of Rs 400. This signals an upside potential of up to 32 per cent.
Market in consolidation mode; triggers needed, says Sunil Subramaniam
Indian pharma stocks are rebounding, driven by domestic investors after a period of Foreign Institutional Investor (FII) selling pressure. Uncertainty surrounding potential US tariffs, fueled